Response and Healthcare Resource Utilization in Inflammatory Bowel Disease Patients Treated with Either Infliximab or Vedolizumab

Harry E. Sarles – DHAT Research Institute, Richardson, TX
Thomas C. Hardin – Healix Infusion Therapy, Sugar Land, TX
Samantha A. Kuten – Healix Infusion Therapy, Sugar Land, TX
Lucinda J. Van Anglen – Healix Infusion Therapy, Sugar Land, TX